Welcome to our dedicated page for Cadrenal Therapeutics SEC filings (Ticker: CVKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cadrenal Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cadrenal Therapeutics's regulatory disclosures and financial reporting.
Cadrenal Therapeutics director and CEO Quang X Pham reported open-market sales of company stock. He sold a total of 18,124 shares of Cadrenal Therapeutics, Inc. common stock in three transactions on June 11, 12 and 15, 2026, at weighted average prices of $4.12, $3.94 and $3.58 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following these transactions, Pham holds 132,715 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.
CVKD reported multiple resale transactions of Common Stock by Quang X. Pham under Form 144. The filing lists individual dispositions on several dates in May–June 2026, including sales of 12,996 shares on 06/12/2026 and 12,992 shares on 06/09/2026.
The record also shows a line identifying Founders Shares: 40,000 shares (01/25/2022). The filing lists each sale with the number of shares and gross proceeds per trade; cash‑flow treatment is the selling holder's proceeds.
Cadrenal Therapeutics, Inc. Chairman, CEO and Interim CFO Quang X Pham reported open-market sales of a total of 22,385 shares of common stock over three days. Shares were sold at weighted average prices of about $4.38 on June 8, $4.06 on June 9, and $4.21 on June 10, in transactions described as carried out under a Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following these sales, Pham holds 150,839 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power.
Cadrenal Therapeutics, Inc. CEO and Chairman Quang X. Pham reported open-market sales of a total of 8,285 shares of common stock on June 3–5, 2026 at weighted average prices of $4.26, $4.41 and $4.42 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following the transactions, he holds 173,224 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power.
Cadrenal Therapeutics, Inc. reported that Chief Financial Officer Matthew K. Szot mutually agreed to transition out of his role effective May 28, 2026. Immediately afterward, the company appointed Chief Executive Officer Quang X. Pham as interim Chief Financial Officer and interim Principal Accounting Officer while it conducts a search for a permanent CFO.
Under a Severance Agreement dated June 3, 2026, Mr. Szot is entitled to a cash severance of $365,806.00 paid in four installments and his fiscal 2026 target cash bonus of $237,903.00 paid in two installments, all subject to standard deductions and withholdings. All of his outstanding stock options will fully vest and remain exercisable until their original expiration dates. The agreement includes a seven-day Revocation Period, a general release of claims, and a non-disparagement clause.
Cadrenal Therapeutics, Inc. CEO and Chairman Quang Pham reported small open-market sales of company common stock. He sold 303 shares on May 29, 2026 at a weighted average price of $5.01 per share and 349 shares on June 2, 2026 at a weighted average price of $4.46 per share, totaling 652 shares. The sales were executed under a pre-arranged Rule 10b5-1 trading arrangement. After these transactions, Pham holds 181,509 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.
Cadrenal Therapeutics, Inc. CEO and Chairman Quang X Pham reported open-market sales of 12,763 shares of common stock. The sales occurred on May 11, May 12, and May 28, 2026, at reported weighted average prices of $5.76, $5.28, and $4.93 per share.
The footnotes state these transactions were made under a Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following the latest sale, Pham holds 182,161 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power. The filing also corrects an earlier understatement of indirect holdings on a prior Form 4.
Cadrenal Therapeutics CEO and Chairman Quang Pham reported an open-market sale of 1,165 shares of Common Stock on May 22, 2026 at a weighted average price of $5.69 per share, executed as an "S" code transaction.
The sale was made pursuant to a Rule 10b5-1 trading arrangement adopted on September 25, 2025, meaning it was pre-arranged. After the sale, Pham directly owns 194,924 shares of Cadrenal Therapeutics common stock and indirectly holds 20,000 shares through The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power.
Cadrenal Therapeutics reported first quarter 2026 results and outlined next steps for its lead drug CAD-1005 in heparin-induced thrombocytopenia (HIT). Operating expenses fell to $2.5 million from $3.9 million a year earlier, narrowing the net loss to $2.5 million from $3.8 million.
As of March 31, 2026, the company held $2.3 million in cash and cash equivalents and later completed a $2.5 million financing to support near-term development. After receiving official End-of-Phase 2 FDA meeting minutes, Cadrenal plans a randomized, blinded, placebo-controlled Phase 3 registration trial of CAD-1005 added to standard care in HIT.